Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,982 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M, Akiyama Y, Aoki T, Hagiwara K, Takahashi T, Hironaka K, Teranishi F, Osuka F, Takeuchi M, Fujii M, Nakajima T. Kochi M, et al. Among authors: takahashi t. Cancer Chemother Pharmacol. 2013 Nov;72(5):1097-102. doi: 10.1007/s00280-013-2292-9. Epub 2013 Sep 22. Cancer Chemother Pharmacol. 2013. PMID: 24057041 Clinical Trial.
Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
Takahashi T, Shibata Y, Tojima Y, Tsuboi K, Sakamoto E, Kunieda K, Matsuoka H, Suzumura K, Sato M, Naganuma T, Sakamoto J, Morita S, Kondo K. Takahashi T, et al. Int J Clin Oncol. 2013 Apr;18(2):335-42. doi: 10.1007/s10147-012-0382-z. Epub 2012 Mar 2. Int J Clin Oncol. 2013. PMID: 22383023 Clinical Trial.
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Shigekawa T, Osaki A, Sekine H, Sato N, Kanbayashi C, Sano H, Takeuchi H, Ueda S, Nakamiya N, Sugitani I, Sugiyama M, Shimada H, Hirokawa E, Takahashi T, Saeki T. Shigekawa T, et al. Among authors: takahashi t. BMC Cancer. 2015 Apr 10;15:253. doi: 10.1186/s12885-015-1289-7. BMC Cancer. 2015. PMID: 25884795 Free PMC article.
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H, Maeda H, Hasegawa J, Takahashi T, Hazama S, Fukunaga M, Kono E, Kotaka M, Sakamoto J, Nagata N, Oba K, Mishima H. Soda H, et al. Among authors: takahashi t. BMC Cancer. 2015 Oct 14;15:695. doi: 10.1186/s12885-015-1685-z. BMC Cancer. 2015. PMID: 26467662 Free PMC article. Clinical Trial.
A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).
Yoshida M, Takagane A, Miyake Y, Shimada K, Nagata N, Sato A, Ogata Y, Fukunaga M, Otsuka K, Takahashi T, Matsumoto H, Kagimura T, Tsuji A. Yoshida M, et al. Among authors: takahashi t. Oncology. 2016;91(1):24-30. doi: 10.1159/000446372. Epub 2016 May 28. Oncology. 2016. PMID: 27229742 Free article. Clinical Trial.
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T, Emi Y, Oki E, Kobayashi K, Tsuji A, Shimokawa M, Tanaka T, Akagi Y, Ogata Y, Baba H, Yoshida K, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Takahashi T, et al. Cancer Chemother Pharmacol. 2016 Sep;78(3):585-93. doi: 10.1007/s00280-016-3109-4. Epub 2016 Jul 28. Cancer Chemother Pharmacol. 2016. PMID: 27468920 Clinical Trial.
The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. Kataoka M, et al. Among authors: takahashi t. Ann Surg Oncol. 2017 Feb;24(2):546-553. doi: 10.1245/s10434-016-5557-9. Epub 2016 Sep 8. Ann Surg Oncol. 2017. PMID: 27638675 Clinical Trial.
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Matsuda C, Honda M, Tanaka C, Kondo K, Takahashi T, Kosugi C, Tokunaga Y, Takemoto H, Kim HM, Sakamoto J, Oba K, Mishima H. Matsuda C, et al. Among authors: takahashi t. Cancer Chemother Pharmacol. 2018 Jun;81(6):1035-1041. doi: 10.1007/s00280-018-3568-x. Epub 2018 Apr 11. Cancer Chemother Pharmacol. 2018. PMID: 29644459 Clinical Trial.
14,982 results
You have reached the last available page of results. Please see the User Guide for more information.